We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer (DIRECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03899649
Recruitment Status : Recruiting
First Posted : April 2, 2019
Last Update Posted : December 20, 2022
Information provided by (Responsible Party):
Angiodynamics, Inc.

Brief Summary:
This multicenter, observational study will evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC). Eligible patients will be recruited over a 36-month period and participating institutions will enroll and provide data on consecutive patients that meet inclusion and exclusion criteria. Each patient will be followed up for the duration of the study or until death. The study will include two (2) cohorts: patients who received standard of care (SOC) and received irreversible electroporation (IRE) [IRE cohort], and patients who were treated with SOC and did not receive IRE [SOC cohort].

Condition or disease Intervention/treatment
Stage III Pancreatic Cancer Drug: SOC Device: NanoKnife System

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 532 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 24 Months
Official Title: Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma
Actual Study Start Date : May 8, 2019
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
IRE Cohort
Patients who received SOC and received IRE
Drug: SOC
Standard of Care treatment

Device: NanoKnife System
Irreversible Electroporation

SOC Cohort
Patients who received SOC and did not receive IRE
Drug: SOC
Standard of Care treatment

Primary Outcome Measures :
  1. Overall Survival [ Time Frame: Time (in months) from time of enrollment to the date of death for any reason, assessed up to 24 months. ]
    To evaluate the effectiveness of the NanoKnife System when used for the ablation of Stage 3 PC in real world treatment settings, by testing the hypothesis that IRE with the NanoKnife System improves overall survival (OS)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with cytologically or pathologically confirmed Stage 3 PC who are treated, in real-world treatment settings and as part of routine clinical practice, with the NanoKnife System (at least 266 patients) for the ablation of their tumor in addition to SOC (IRE cohort), or with SOC only (at least 266 patients) (SOC cohort). Patients will be enrolled after completing the initial 3-month treatment per SOC for Stage 3 PC.

Inclusion Criteria:

  1. Provisions of signed and dated informed consent form
  2. Patient is 18 years of age and older
  3. Patient has a diagnosis of Stage 3 PC cytologically or pathologically confirmed per American Joint Committee on Cancer (AJCC) staging criteria
  4. Patient has a tumor evaluated as Stage 3 according to National Comprehensive Cancer Network (NCCN) guidelines, based on radiographic imaging or exploratory surgery
  5. Maximum axial and anterior to posterior tumor dimension of ≤3.5cm after SOC
  6. Patient has received 3 months of SOC per each participating institution's guidelines
  7. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  8. Patient has an American Society of Anesthesiologists (ASA) classification of physical health status of 1 or 2.
  9. Patients at IRE sites who are deemed eligible for IRE and receive ablation using the NanoKnife System
  10. Patient shows no evidence of disease progression based on NCCN guidelines after completing three (3) months of SOC

Exclusion Criteria:

  1. Participation in an interventional trial for pancreatic cancer during the study data collection period
  2. Pregnant or lactating patients or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 6 months after the last dose of chemotherapy
  3. Patients who are unable to tolerate general anesthetic with full skeletal muscle blockade
  4. Patients with the presence of implanted cardiac pacemakers, defibrillators, electronic devices or implanted devices with metal parts in the thoracic cavity at the time of IRE

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03899649

Layout table for location contacts
Contact: Elizabeth Manning (339) 237-2765 liz.manning@angiodynamics.com

Layout table for location information
United States, California
Moores Cancer Center, UC San Diego Health Recruiting
La Jolla, California, United States, 92093
Contact: Shakeela Dad         
Principal Investigator: Rebekah White, MD         
University of California, Irvine Recruiting
Orange, California, United States, 92868
Contact: Rebecca Freeman       freemar1@hs.uci.edu   
Principal Investigator: Nadine Abi-Jaoudeh, MD         
United States, Florida
University of Florida Health Active, not recruiting
Gainesville, Florida, United States, 32608
Miami Cancer Institute Recruiting
Miami, Florida, United States, 33176
Contact: Ernesto Cue Barroso         
Principal Investigator: Govindarajan Narayanan, MD         
United States, Georgia
Wellstar Medical Group Active, not recruiting
Marietta, Georgia, United States, 30060
United States, Illinois
Northwest Community Hospital Recruiting
Arlington Heights, Illinois, United States, 60005
Contact: Karen Zwicky         
Principal Investigator: Malcolm M Bilimoria, MD         
United States, Iowa
University of Iowa Healthcare Recruiting
Iowa City, Iowa, United States, 52242
Contact: Laura Jacobus         
Principal Investigator: Carlos Chan, MD         
United States, Kentucky
Norton Healthcare Recruiting
Louisville, Kentucky, United States, 40202
Contact: Mary Healey         
Principal Investigator: Robert Martin, MD, PhD, FACS         
United States, Minnesota
Mayo Clinic, Rochester Recruiting
Rochester, Minnesota, United States, 55905
Contact: Danielle Patnode         
Principal Investigator: Sean Cleary, MD         
United States, Missouri
Barnes-Jewish Hospital Active, not recruiting
Saint Louis, Missouri, United States, 63110
United States, New York
NYU Langone Recruiting
New York, New York, United States, 10016
Contact: Xiaohong Jing         
Principal Investigator: Theodore Welling, MD         
Presbyterian Hospital, Columbia Recruiting
New York, New York, United States, 10032
Contact: Susie Flores         
Principal Investigator: Michael Kluger, MD         
United States, North Carolina
Atrium Health Active, not recruiting
Charlotte, North Carolina, United States, 28204
United States, Pennsylvania
St. Luke's University Health Network Active, not recruiting
Easton, Pennsylvania, United States, 18045
United States, Texas
University of Texas-Southwestern Active, not recruiting
Dallas, Texas, United States, 75231
Sponsors and Collaborators
Angiodynamics, Inc.
Additional Information:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Angiodynamics, Inc.
ClinicalTrials.gov Identifier: NCT03899649    
Other Study ID Numbers: 2019-ONC-02
First Posted: April 2, 2019    Key Record Dates
Last Update Posted: December 20, 2022
Last Verified: December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Angiodynamics, Inc.:
Pancreas Cancer
Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Advanced Pancreatic Cancer
Carcinoma, Pancreatic Ductal
Locally Advanced Pancreatic Cancer
Cancer of Pancreas
Pancreatic Tumor
Pancreatic Carcinoma
Unresectable Pancreatic Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases